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Abstract 
Background: Metastasis to long distance organs is the main reason leading to morality of tongue squamous cell 
carcinoma (TSCC); however, the molecular mechanisms are still unknown. High mobility group AT‑hook 2 (HMGA2) 
is highly expressed in multiple metastatic carcinomas, in which it contributes to cancer progression, metastasis and 
poor prognosis by upregulating Snail expression and inducing epithelial mesenchymal transition (EMT). This study 
focuses on investigating the role and mechanism of regulation of HMGA2 in the metastasis of TSCC.
Methods: HMGA2 mRNA and protein expression were examined in TSCC specimens by quantitative real‑time poly‑
merase chain reaction, western blotting and immunohistochemistry (IHC). Western blotting, IHC and immunofluo‑
rescence were also used to measure the expression and localization of EMT marker E‑Cadherin and Vimentin both in 
TSCC cells and tissues. Knockdown assay was performed in vitro in TSCC cell lines using small interfering RNAs and the 
functional assay was carried out to determine the role of HMGA2 in TSCC cell migration and invasion.
Results: TSCC mRNA and protein expression were significantly up‑regulated in tumor tissues when compared to 
adjacent non‑tumor tissues, and the overexpression of HMGA2 was closely correlated with lymph nodes metastasis. 
Clinicopathological analysis indicated that HMGA2 expression was associated with clinical stage (P = 0.001), lymph 
node metastasis (P = 0.000), histological differentiation (P = 0.002) and survival (P = 0.000). Silencing the HMGA2 
expression in Cal27 and UM1 resulted in the inhibition of cell migration and invasion, meanwhile down‑regulation of 
HMGA2 impaired the phenotype of EMT in TSCC cell lines and tissues. The Multivariate survival analysis indicates that 
HMGA2 can be an independent prognosis biomarker in TSCC.
Conclusion: Our findings demonstrate that HMGA2 promotes TSCC invasion and metastasis; additionally, HMGA2 is 
an independent prognostic factor which implied that HMGA2 can be a biomarker both for prognosis and therapeutic 
target of TSCC.
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Background
Tongue squamous cell carcinoma (TSCC) is one of the 
most common and lethal oral cancer [1, 2], which is char-
acterized by its preferring of lymph node and distant 
metastasis [3]. Clinical evidences indicate that metastasis 
is the most important poor prognostic factors for patient 
diagnosis with TSCC [4]. Despite its significance and the 
enormous studies accumulated in the past decades on 
the molecular mechanisms of TSCC progression, little is 
known about the underlying molecular mechanisms reg-
ulating metastatic dissemination.
More and more studies demonstrated that epithelial 
mesenchymal transition (EMT) is a key process which 
has been shown to be of critical biological function and 
significance during embryogenesis and carcinogenesis 
[5–7]. Increasing evidences have recognized that the 
epithelial to mesenchymal transition (EMT), a driver of 
invasion and metastasis of cancer, may play a pivotal role 
in multiple types of tumor cell metastatic dissemination 
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High mobility group 2 (HMGA2) is a chromatin 
remodeling factor which can change the chromatin 
architecture to activate or impair the activity of tran-
scriptional enhancers [12]. HMGA2 is highly expressed 
in most malignant epithelial tumors, including breast 
cancer [13, 14], colorectal cancer [15], gastric cancer 
[16], lung cancer [17], melanoma [18], myeloid [19], 
oral cancer [20], ovarian cancer [21], pancreas cancer 
[22], pituitary adenomas [23, 24]. HMGA2 overexpres-
sion in transgenic mice causes tumorigenesis; however, 
HMGA2-knockout in mice can severely impair the 
mice growth and development, leading a nanous shape 
[25].
Despite the fact that both the HMGA2 and EMT play 
a significant role in the development and progression of 
TSCC, the relationship between these factors has not yet 
been reported in TSCC. In the present study, we dem-
onstrate that overexpression of HMGA2 is closely asso-
ciated with progression and poorer overall survival in 
human TSCC, and provide evidence that the expression 
of HMGA2 can promote the progression of TSCC by 
upregulating Snail and inducing the EMT.
Methods
Patients and tissue samples
A total of 60 human TSCC tissues and 20 adjacent non-
tumor tissue samples were examined in this study. The 
patients were histopathologically and clinically diag-
nosed at Sun Yat-sen Memorial Hospital, Sun Yat-sen 
University from 2008 to 2010; the pathological diagnosis 
was verified for each case. For each case, tumor samples 
with matched adjacent non-tumor tissue samples were 
collected during surgical resection and frozen in liquid 
nitrogen and stored at −80  °C. Sample collection was 
performed in accordance with the policies of the National 
Research Ethics Committee and informed consent was 
obtained from each patient. The clinicopathological fea-
tures of the patients are summarized in Table 1.
Cell lines and cell cultures
The human TSCC cell Cal27, SCC9, SCC15, SCC25 and 
UM1 were used in our study. Cal27, SCC9, SCC15 and 
SCC25 cell lines were obtained from American Type Cul-
ture Collection (ATCC; Manassas, VA, USA) and UM1 
was reserved by our lab. Cal27 cells were maintained in 
DMEM medium (Invitrogen, Carlsbad, CA, USA) sup-
plemented with 10 % fetal bovine serum (FBS) and other 
cells were cultured in RPMI-1640 medium supplemented 
with 10  % FBS. For all TSCC cell lines, 1  % penicillin/
streptomycin was added to the culture medium and all 
TSCC cell lines were cultured at 37  °C in a humidified 
atmosphere containing 5 % CO2.
RNA extraction, reverse transcription and quantitative 
real‑time PCR (qRT‑PCR)
For total RNA isolation, tumor specimens were finely 
minced with scissors and homogenized, then, the total 
RNA from fresh surgical tongue tissues and TSCC cells 
were extracted using the TRIzol reagent (Invitrogen, 
Carlsbad, California, USA) according to the manufac-
turer’s instructions. Complementary DNA (cDNA) 
was synthesized with the PrimeScript RT reagent Kit 
(TaKaRa, Dalian, China) primed with random hexam-
ers. For amplification of HMGA2, reverse transcription 
PCR was programmed as follows: 95  °C for 2  min, 30 
cycles of 94 °C for 30 s, 56 °C for 30 s, 72 °C for 45 s, 72 °C 
for 10  min, hold at 4  °C. The primer was as followed: 
HMGA2 forwared: 5′-AAGTTGTTCAGAAGAAGCCT 
GCTCA-3′; HMGA2 reverse: 5′-TGGAAAGACCATG 
GCAATACAGAAT-3′. RT-PCR products were analyzed 
via 2.0  % agarose gel electrophoresis and stained with 
ethidium bromide for visualization using ultraviolet light. 
Real-time PCR was performed with LightCycler Real 
Time PCR System (Roche Diagnostics, Switzerland) and 
the primer sequences for HMGA2 was used as followed: 
Table 1 Clinicopathological parameters and  HMGA2, 
Snail1 expression in 60 primary tongue carcinomas
Parameter n HMGA2  
staining
P Snail1  
staining
P
Positive (%) Positive (%)
Age 0.863 0.134
 ≤55 34 22 (64.7) 17 (50.0)
 >55 26 15 (57.7) 8 (30.8)
Sex 0.005 0.394
 Female 23 9 (39.1) 8 (34.8)
 Male 37 28 (75.7) 17 (45.9)
T stage 0.074 0.895
 T1 + T2 33 17 (63.6) 14 (45.5)
 T3 + T4 27 20 (81.5) 11 (59.3)
Clinical stage 0.001 0.003
 I + II 23 8 (34.8) 4 (17.4)
 III + IV 37 29 (78.4) 21 (56.8)
N status 0.000 0.000
 N− 35 14 (40.0) 6 (17.1)




 Well 24 9 (37.5) 4 (16.7)
 Moderate/ 
poor
36 28 (77.8) 21 (58.3)
Survival 0.000 0.001
 Survival 32 11 (34.4) 7 (21.9)
 Die 28 26 (92.9) 18 (64.3)
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(F) 5′-AAAGCAGCTCAAAAGAAA GCA-3′; (R) 5′-TG 
TTGTGGCCATTTCCTAGGT-3′.
RNA interference
Short interfering RNA (siRNA) against HMGA2 and cor-
responding GFP siRNA (GFP-si) were synthesized and 
purchased from GenePharma Company (GenePharma, 
Shanghai, China). The two siRNAs specific against 
HMGA2 sequences were as followed: HMGA2-siRNA1: 
CACAACAAGUCGUUCAGAA; and HMGA2-siRNA2: 
AGAGGCAGACCUAGGAAAU. Transfection was per-
formed in 6-well plates using Lipofectamine 2000 (inviz-
trogen) following the manufacturer’s instructions. The 
gene silencing efficiency was detected by western blotting 
after transfection.
Western blotting
Equal amounts of protein extracts were separated using 
10 % polyacrylamide SDS gels (SDS–PAGE), transferred 
onto polyvinylidene fluoride (PVDF) membranes (Amer-
sham Pharmacia Biotech) and the membranes were 
probed with antibody against human HMGA2 (1:1000, 
Cell Signal Technology, Danvers, MA, USA), E-cad-
herin, vimentin, snail (1:500, Santa Cruz, Santa Cruz, 
CA, USA), or GAPDH (1:3000, Proteintech, Chicago, IL, 
USA), and then with peroxidase-conjugated secondary 
antibody (1:3000, Proteintech) and the signals were visu-
alised by enhanced chemiluminescence kit (GE, Fairfield, 
CT, USA) according to the manufacturer’s instructions. 
Anti-GAPDH antibody (Proteintech) was used as a load-
ing control.
Modified boyden chamber assay
A total of 1 × 105 cells were plated into the upper cham-
ber of a polycarbonate transwell filter chamber (Corning, 
New York, NY, USA) and incubated for 10  h. For inva-
sion assay, the upper chamber was coated with Matrigel 
(R&D, Minneapolis, MN, USA) and incubated for 24  h. 
The non-invading cells were gently removed with a soft 
cotton swab, and the cells that had invaded to the bottom 
chamber were fixed, stained, photographed and counted.
Immunofluorescence analysis
Cells were seeded on glass coverslips, cultured, fixed 
and subjected to immunofluorescent analysis by incuba-
tion overnight at 4 °C with antibodies against E-cadherin 
or vimentin (1:100, Santa Cruz, Santa Cruz, CA, USA). 
After washing several times, the cells were incubated 
with Alexa Fluor 594-conjugated secondary antibodies 
(1:500, Invitrogen, USA) for 1  h at room temperature, 
then the cells were counterstained with DAPI and imaged 
by confocal laser-scanning microscopy (LSM710, Carl 
Zeiss, Thornwood, NY).
Immunohistochemistry
Immunohistochemical analysis was performed to inves-
tigate the expression of HMGA2, Snail, E-Cadherin and 
Vimentin in different grades of human tongue cancer. 
Briefly, immunohistochemistry (IHC) was performed 
on the paraffin-embedded human tongue cancer tissue 
sections. Antigen retrieval was performed in a pressure 
cooker in citrate solution, pH 6.0, for 15 min, followed by 
treatment with 3 % hydrogen peroxide for 5 min. Speci-
mens were incubated with antibodies as followed: goat 
monoclonal antibodies against HMGA2 (1:100, CST), 
E-cadherin, vimentin, snail (1:100, Santa Cruz, Santa 
Cruz, CA, USA). For the negative controls, isotype-
matched antibodies were applied. The tissue sections 
were observed under a Zeiss AX10-Imager A1 micro-
scope (Carl Zeiss, Thornwood, NY) and all images were 
captured using AxioVision 4.7 microscopy software (Carl 
Zeiss, Thornwood, NY).
Statistical analysis
Statistical analysis was performed using a SPSS software 
package (SPSS Standard version 18.0, SPSS Inc). (SPSS, 
Chicago, IL, USA) Differences between variables were 
assessed by the χ2 test according to Pearson or Fisher’s 
exact test. For survival analysis, we analysed all patients 
with TSCC by Kaplane–Meier analysis. A log rank test 
was used to compare different survival curves. Multi-
variate survival analysis was performed on all parameters 
that were found to be significant in univariate analysis 
using the Cox regression model. Two-tailed Student’s t 
tests were used to determine statistical significance for all 
results. P < 0.05 was considered to be statistically signifi-
cant in all cases.
Results
HMGA2 expression is up‑regulated in TSCC cells lines
Overexpression of HMGA2 has been reported in many 
kinds of human cancers. Its expression status in tongue 
cancer, however, remains unknown. To investigate the 
HMGA2 expression, western blotting analysis were car-
ried out to quantify the expression level of HMGA2 in 
TSCC cell lines. The results demonstrated that HMGA2 
protein was highly expressed in tongue cancer cell lines 
(Fig. 1a). To confirm if the HMGA2 upregulation was also 
apparent at the mRNA level, reverse transcription-PCR 
was performed. As shown in Fig. 1b, in parallel with up-
regulation of the HMGA2 protein, the five tongue cancer 
cell lines unexceptionally showed significantly higher lev-
els of HMGA2 mRNA.
HMGA2 is overexpressed in primary tongue cancer
To determine whether the up-regulation of HMGA2 in 
tongue cancer cell lines is clinically correlated with tongue 
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cancer progression, we did western blotting analysis on 
eight cases of paired primary matched adjacent non-neo-
plastic tongue tissue and tongue cancer samples. As shown 
in Fig. 2a, consistent with the former results, HMGA2 was 
found to be differentially overexpressed in all eight exam-
ined human primary tongue cancer samples compared 
with their matched adjacent non-neoplastic tissues from 
the same patients. This result is also can be obtained in real-
time reverse transcription-PCR (Fig. 2b). Furthermore, this 
finding is consistent with the results obtained in our immu-
nohistochemical staining analysis in four pairs of primary 
tongue cancer tissues and adjacent non-neoplastic tissues 
(Fig. 2c). Additionally, using quantitative real-time PCR, 20 
cases of paired primary matched adjacent non-neoplastic 
tongue tissue and tongue cancer samples were analyzed, 
most of cases had much higher HMGA2 expression lev-
els, compared with adjacent non-neoplastic tongue tissues 
(Fig.  2d). All of these results indicate that HMGA2 was 
upregulated in tongue cancer cell lines and human tissues.
Overexpression of HMGA2 was associated with a poor 
prognostic phenotype of TSCCs
To further investigate the clinicopathological and prog-
nostic significance of HMGA2 levels in patients with 
TSCC, the levels of HMGA2 in a large cohort of 60 TSCC 
tissues were examined by qRT-PCR and then verified by 
IHC. Using qRT-PCR, the correlation between HMGA2 
expression and metastatic status was analyzed in 60 TSCC 
samples. The result showed that, 39/60 (65 %) TSCC had 
much higher expression of HMGA2, which was signifi-
cantly associated with a more aggressive tumor pheno-
type (P < 0.001, Fig.  2e). To further confirm the verified 
the results above, IHC was performed in all the 60 TSCC 
samples. The median value of all 60 TSCC samples was 
chosen as the cut-off point for separating tumors with 
negative expression of HMGA2 from positive expression 
HMGA2 tumors; thus 37/60 (61.7  %) TSCCs had posi-
tive expression of HMGA2, while 23/60 (38.3 %) TSCCs 
had negative expression of HMGA2 (Table  1). Further-
more, as shown in Table 1, HMGA2 expression strongly 
correlated with clinical stage (P  =  0.001), lymph node 
status (P = 0.000), histological differentiation (P = 0.002) 
and survival (P =  0.000) in patients with tongue cancer; 
however, the analysis data indicated that HMGA2 expres-
sion was not correlated with age and tumor stage. Taken 
together, our analyses revealed that the expression of 
HMGA2 was upregulated during the clinical progres-
sion of tongue cancer, indicating that the expression of 
HMGA2 may promote the progression of tongue cancer.
Association between HMGA2 expression and patient 
survival
Patient survival analysis presented in Table  1 indicated 
a clear positive correlation between HMGA2 protein 
expression level and the overall survival time in tongue 
cancer patients. The effects of classic clinicopathologic 
features, including age, gender, clinical stage, tumor stage 
(T stage), lymph node status (N status), distant metas-
tasis, in conjunction with HMGA2 protein expression, 
on patient survival, were examined with Kaplan–Meier 
analysis and the log-rank test. As shown in Fig.  3a, the 
length of overall survival time varied significantly differ-
ent between patients with negative and positive HMGA2 
expression (P < 0.01), with the negative HMGA2 expres-
sion group having a longer overall survival time, com-
pared with those with high level expression of HMGA2. 
In addition, the prognostic value of HMGA2 expression 
in patient was also evaluated according to the lymph 
node metastasis, clinical stage and T stage. The analysis 
results revealed that the patients with tumors exhibiting 
low expression of HMGA2 have less possibility of lymph 
node metastasis (Fig.  3b), well prognosis of clinical and 
tumor stage (Fig. 3c, d).
When univariate and multivariate analyses were done 
to determine whether HMGA2 expression is an inde-
pendent prognostic factor of patient outcomes, as Table 2 
shows, HMGA2 expression (P = 0.042), as well as clini-
cal stage (P  =  0.028), was recognized as independent 
prognostic factors. Taken together, our data suggest that 
HMGA2 might represent a novel and potentially useful 
independent biomarker for the prognosis of patients with 
tongue squamous cell carcinoma.
Down‑regulation HMGA2 expression inhibited tongue 
cancer cell migration and invasion in vitro
As HMGA2 expression was positively related with 
lymph node metastasis and metastasis to distant organs 
Fig. 1 Overexpression of HMGA2 in human tongue cancer cell lines. 
a Western blotting analysis of HMGA2 protein in tongue squamous 
cell carcinoma (TSCC) cell lines. GAPDH was probed as loading 
control. b Real‑time PCR analysis of HMGA2 mRNA expression level in 
tongue cancer cell lines
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contributes to poorer survival, next we investigate the 
effect of HMGA2 on the migration and invasion of Cal27 
epithelial tongue cancer cell and UM1 mesenchymal 
tongue cancer cell. Firstly, the cell lines were treated with 
two specific siRNAs against HMGA2 and the silence effi-
ciency was examined by western blotting in these two cell 
lines. As shown in Fig. 4a, both siRNAs efficiently knocked 
down the endogenous expression of HMGA2 protein in 
Cal27 and UM1 cells. Using the transwell chamber model, 
we observed that compared to untreated or vector trans-
fecting tongue cancer cells, silencing of HMGA2 expres-
sion severely inhibited the migration and invasion ability 
of Cal27 and UM1cells (Fig.  4b–e). Similar results were 
also observed in wound healing assay (data not shown). 
These results indicated that the expression of HMGA2 
promotes the metastatic ability of tongue cancer cells.
HMGA2 promotes EMT phenotype in tongue cancer cells
The results above demonstrate that overexpression of 
HMGA2 is associated with poorer survival in patients 
with tongue cancer; however, the mechanism and fac-
tors downstream of HMGA2 which mediate this effect 
are unknown. It has been reported that HMGA2 can 
induce and promote several cancer cells EMT by up-
regulating Snail expression [26]. Furthermore, activation 
of the EMT is a universal phenomenon in multiple types 
of cancer [27]. Then, western blotting and immunofluo-
rescence (IF) were performed to investigate the expres-
sion of markers of the EMT in tongue cancer cells. We 
found that in both Cal27 epithelial tongue cancer cells 
and UM1 mesenchymal tongue cancer cells, silencing of 
HMGA2 inhibited the expression of Snail and two classi-
cal mesenchymal cell markers, N-cadherin and vimentin, 
whereas the epithelial cell marker, E-cadherin expression 
was elevated, indicating that there is a potential corre-
lation between HMGA2 and Snail (Fig.  5a). The similar 
results can be found by IF analysis in both Cal27 and 
UM1 tongue cancer cells (Fig.  5b). These results imply 
that the expression of HMGA2 may promote metastasis 
in tongue cancer by activating the EMT.
Fig. 2 HMGA2 is upregulated in histopathological sections of tongue cancer and high expression of HMGA2 is correlated with tumorigenesis and 
metastasis. a Western blotting analysis of HMGA2 protein in eight human primary tongue cancer (T) and paired adjacent non‑tumor tongue tissues 
(N), with each pair taken from a same patient. b Quantitative real time RT‑PCR analysis of HMGA2 mRNA from the same eight pairs of tongue cancer 
and adjacent non‑tumor tongue tissues. Error bars represent SDs calculated from three parallel experiments. c HMGA2 expression levels were up‑
regulated in primary tongue tumor tissues (T) compared to the paired adjacent non‑tumor tongue tissue (N) from the same patient as examined by 
immunohistochemistry. d Expression levels of HMGA2 in 20 paired TSCC and adjacent non‑tumor tongue tissues. Alteration of expression is shown 
as box plot presentations and the mean level of HMGA2 expression in TSCCs were significantly higher than that in non‑tumor tissues. (P < 0.001, 
independent t test). e Expression levels of HMGA2 between 60 TSCCs with and without metastasis. The mean level of HMGA2 expression in TSCCs 
with metastasis were significantly higher than that in TSCCs without metastasis (P < 0.001, independent t test)
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Snail is potential involved in tongue cancer EMT activated 
by HMGA2
Previous reports have revealed that Snail was an impor-
tant transcriptional factor which can directly induce 
EMT in multiple cancers [28, 29]. Our data indicated 
that Snail is potentially involved in the EMT induction 
by interaction with HMGA2 in tongue cancer. To further 
demonstrate the correlation between HMGA2 and Snail 
during the EMT process in tongue cancer, the expres-
sion of HMGA2, Snail and EMT markers, E-cadherin and 
Vimentin were examined in different differential stage 
tongue cancer tissues. As Fig. 6a shown, the poorly-dif-
ferentiated tongue cancer tissue expressed much higher 
levels of HMGA2, Snail and Vimentin, but lower level of 
E-cadherin, than the well differentiated tongue cancer tis-
sue, compared to the normal tongue tissues (Fig. 6a). As 
tongue cancer cells preferred to transfer to lymph nodes, 
we examined the expression of HMGA2 and Snail in the 
metastatic lymph nodes [30, 31]. We found that both 
HMGA2 and Snail are highly expressed and co-local-
ized in the nuclear of lymph nodes (Fig.  6b), indicating 
that there may be an interaction between HMGA2 and 
Fig. 3 Kaplan–Meier analysis of TSCC patients with positive HMGA2 expression versus those that negative HMGA2 expression. a Overall survival 
rate for cases with positive HMGA2 expression versus that of cases with negative HMGA2 expression; b HMGA2 expression status for overall survival 
rate stratified by lymph node metastasis condition; c overall survival rate for cases categorized with clinical stage classification and HMGA2 expres‑
sion status; d HMGA2 expression level for overall survival rate stratified by tumor stage classification
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Snail, which may play an significant role in the metastasis 
process through EMT pathway activated by HMGA2 in 
tongue cancer.
To further illustrate the relationship between HMGA2 
and Snail, the correlation between HMGA2 and Snail were 
analyzed by Person analysis and the result indicated that 
there is a positive correlation between them (R2 = 0.8876, 
P  <  0.000, Fig.  6c). The clinicopathological and prognos-
tic significance of Snail in tongue cancer is also analyzed 
by immunohistochemical staining. As shown in Table  1, 
Snail expression strongly correlated with clinical stage 
(P = 0.003), lymph node metastasis (P = 0.000), histologi-
cal differentiation (P  =  0.001) and survival (P  =  0.001). 
However, multivariate survival analysis revealed that Snail 
expression was not an independent prognostic factor 
(P  =  0.97), whereas HMGA2 was (P  =  0.042) (Table  2). 
Collectively, these findings indicate that HMGA2 protein 
expression, but not Snail protein expression, correlates sig-
nificantly with the prognosis of patients with tongue cancer.
Discussion
TSCC is a common and considerable threat to human 
health in the worldwide. Many researchers have explored 
the underlying mechanisms which may regulate cancer 
cell progression in TSCC. It is believed that metastasis 
is an essential feature of cancer and contributes to the 
majority of cancer-related deaths in humans and several 
signal pathways are involved in this procession, includ-
ing EMT [27, 32, 33]. Epithelial–mesenchymal transition 
(EMT) is a process whereby tumor cells lose the epithe-
lial features to acquire a mesenchymal phenotype and 
become motile and invasive, which is closely associated 
with metastasis [27, 34].
It has been reported that tumor cells can dedifferenti-
ate to obtain the capability to migrate and invade, endow-
ing cancer cells to disseminate from the primary tumor 
to distant organs, via triggering specific genes expression 
which associated with EMT signal pathway. Meanwhile, 
EMT is closely regulated by several signal pathways 
and involves regulation networks of transcription fac-
tors, such as Snail, ZEB and Twist family which regulate 
expression of E-cadherin, which is a major suppressor of 
tumor invasiveness and transcriptionally repressed dur-
ing the EMT [35–37].
HMGA2 is one of the members of the high-mobility 
group A (HMGA) family which binds to DNA sequences 
Table 2 Univariate and multivariate analysis of factors associated with disease-free survival of patients with TSCC
Variable N Univariable Multivariable
HR 95 % CI P HR 95 % CI P
Age
 ≤55 34 1
 >55 26 0.615 0.234–1.617 0.324
Sex
 Male 37 1 1
 Female 23 0.317 0.128–0.784 0.013 0.790 0.649–2.175 0.649
Differentiation
 Well 24 1 1
 Moderate/poor 36 3.829 1.537–9.538 0.004 2.323 0.760–7.103 0.139
T stage
 T1 + T2 33 1 1
 T3 + T4 27 3.638 1.638–8.082 0.002 1.087 0.397–2.972 0.871
N status
 N− 35 1 1
 N+ 25 7.706 3.206–18.522 0.000 1.501 0.4594–4.908 0.501
Clinical stage
 I + II 23 1 1
 III + IV 37 8.873 3.902–13.623 0.001 13.806 1.333–143.024 0.028
HMAG2 staining
 Negative 23 1 1
 Positive 37 14.779 3.431–63.665 0.000 5.785 1.066–31.391 0.042
Snail staining
 Negative 35 1 1
 Positive 25 3.819 1.738–8.393 0.001 0.976 0.280–3.402 0.970
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Fig. 4 Down‑regulation of HMGA2 inhibited TSCC cell motility and invasion. a The knockdown efficiency of two specific siRNA against HMGA2 
was examined by Western blotting in Cal27 and UM1 cells. b The migration and c invasiveness abilities were analyzed in an epithelial type tongue 
cancer cell Cal27 by Boyden chamber assay (scale bar: 200 μm, * P < 0.05, ** P < 0.01). d The migration and e invasiveness abilities were analyzed in a 
mesenchymal like tongue cancer cell UM1 by Boyden chamber assay (scale bar: 200 μm, ** P < 0.01)
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to orchestrate transcription activity by modulating chro-
matin structure. Besides, HMGA2 is frequently highly 
expressed in undifferentiated cells during embryogenesis, 
but silenced in most of the normal adult tissues [21, 38]. 
So, HMGA2 rarely can be detected in normal adult tis-
sues but is usually reactivated in a variety of benign and 
malignant tumors. Furthermore, highly expression of 
HMGA2 has been correlated with cancer proliferation, 
increased metastasis and poor prognosis in multiple 
types of cancer [4].
It has been described that up-regulation of HMGA2 
can activate the Snail, Twist and ZEB families expression 
and induce EMT process, which leads to tumor metas-
tasis in various cancers [14]. In this study, our results are 
consistent with numerous prior studies that HMGA2 is 
up-regulated both in TSCC cell lines and tissues; the high 
level expression of HMGA2 can activate the EMT pro-
cess by repressing E-cadherin expression and the up-reg-
ulating of HMGA2 is closely associated with metastasis 
and poor prognosis in tongue squamous cell carcinoma. 
Meanwhile, previous researches have implied that Smad, 
TGF-β canonical pathway and NF-κB signal pathway also 
contribute to EMT procession through associating with 
HMGA2 [26, 39, 40]. We show that the overexpression 
of HMGA2 can up-regulate Snail expression level and 
activate EMT, leading to poor clinical stage (P = 0.001), 
lymph node status (P =  0.000), poor histological differ-
entiation (P =  0.002) and short survival (P =  0.000) in 
patients with tongue cancer. Interestingly, although Snail 
play a pivotal role in the regulating of EMT, multivari-
ate survival analysis shown that Snail expression was not 
an independent prognostic factor (P  =  0.97), whereas 
HMGA2 was (P = 0.042), implying that HMGA2 may be 
an independent prognosis biomarker in the tongue squa-
mous cell carcinoma.
MicroRNA can regulate gene expression by binding 
to the 3′-untranslational region (3′-UTR) to degrade the 
target genes expression. In previous studies, HMGA2 
Fig. 5 Knockdown of HMGA2 can reversed epithelial–mesenchymal transition (EMT). a The expression of EMT markers of E‑Cadherin, Vimentin, 
N‑Cadherin and Snail were analyzed by western blotting both in Cal27 and UM1 tongue cancer cells. GAPDH was probed as the loading control. b 
Immunofluorescence staining analysis EMT markers of E‑Cadherin and Vimentin (red) using confocal and the nuclei were stained with DAPI (blue) 
(scale bar: 5 μm)
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was identified as the target gene of several microRNAs, 
such as Let-7, which is considered to be a tumor sup-
pressor gene in multiple types of cancer [41–44]. Several 
researches have revealed a new function and mechanism 
of HMGA2 as a competing endogenous to promote lung 
cancer progression [17, 45].
Lymph node metastasis is the predominant invasive 
site of TSCC and predicted a poor prognosis [31]. Our 
results show that overexpression of HMGA2 is closely 
associated with lymph node metastasis and immunohis-
tochemical staining indicate that both HMGA2 and Snail 
are upregulated and co-localized in the nuclear. Correla-
tion analysis also confirms that there is a positive correla-
tion between them, implying the promoting cooperation 
during the TSCC progression.
In summary, our study demonstrated that HMGA2 
was upregulated and positively associated with the 
overall survival, clinical stage, T classification and 
N classification. Moreover, HMGA2 expression is 
positively correlated with Snail expression in TSCC 
patients, implying the interaction between each other. 
In addition, knockdown of HMGA2 expression can 
severely impair tongue cancer cells migration, invasion 
and EMT process. This study suggests that HMGA2 
may play a pivotal role in tumor metastasis and can be 
a novel diagnostic marker and potential therapeutic tar-
get in TSCC.
Conclusions
In sum, overexpression of HMGA2 promotes tongue can-
cer cell migration and invasion in vitro. In addition, up-
regulation of HMGA2 was closely associated with poor 
prognosis in tongue cancer patients. HMGA2 enhances 
tongue cancer metastasis and progression via interaction 
with Snail through EMT signal pathway. Together, our 
findings suggest that HMGA2 participates in the pro-
gression of TSCC via Snail through EMT.
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